International partnership networks in regenerative medicine

DON’T MISS OUR LAST BIOBREAKFAST FOR 2016!

The State Government of Victoria recently announced that the first Australian node of the internationally acclaimed Canadian Centre for Commercialisation of Regenerative Medicine (CCRM) will be set up in Melbourne. This global partnership will connect large multinationals, small-medium enterprises and emerging biotechnology companies with leading academic research organisations to grow the regenerative medicine industry here in Melbourne.

At this BioBreakfast event hear from renowned stem cell scientist Prof Andras Nagy on the lessons from Canada on how collaborative networks can drive technology development, company creation and accelerate the commercialising regenerative medicine technologies and cell-based therapies.

Who should attend? CEOs, CSOs, R&D partnership managers, business development professionals, and anyone with an interest in how to build global networks to translate and commercialise emerging technologies.

Date: Tuesday 6th December, 2016
Time: Registration 7.15am  for 7.30am networking buffet breakfast, followed by a presentation until 9am
Venue: Monash Conference Centre, Level 7, 30 Collins St Melbourne
Speaker: Dr Andras Nagy, PhD, FRSC, Foreign Member of Hungarian Academy of Sciences, Shawn Kimel Research Scientist, Lunenfeld-Tanenbaum Research Institute, Sinai Health System

Cost:

Members: $65
Non-Members: $130
(Prices include GST)

To check if your organisation is a member, click here

International Guest Speaker:

Dr. Nagy is currently a Shawn Kimel Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Professor in the Department of Obstetrics & Gynaecology and Institute of Medical Science at the University of Toronto, Investigator at the McEwen Centre for Regenerative Medicine and Professor at the Monash University, Melbourne. He holds a Tier I Canada Research Chair in Stem Cells and Regeneration. He also has a Fellowship of the Royal Society of Canada in the Life Sciences Division of the Academy of Science and recently became a Foreign Member of the Hungarian Academy of Sciences

Dr. Nagy has made significant breakthroughs in the development of mouse and human pluripotent stem cells (both embryonic and induced) that could accelerate research in regenerative medicine and lead to future therapies for currently incurable diseases, such as blindness, diabetes, arthritis, spinal cord injury and many others. His team created the first two Canadian human embryonic stem cell lines and developed a novel method for generating non-viral induced pluripotent stem cells. His current research focuses on understanding the process of reprogramming to stem cells at the molecular level and using sophisticated genome editing methodology to pave the way leading to safe and effective cell based therapies of diseases.

Supported by: